Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.
CYAD (Celyad Oncology SA) provides a centralized hub for tracking developments in clinical-stage cell therapies and immuno-oncology innovations. This resource aggregates essential updates including trial progress, regulatory milestones, and strategic partnerships critical for evaluating the company's position in cancer treatment research.
Investors and researchers will find curated press releases detailing CYAD's NKR-T cell programs, manufacturing advancements, and collaborative initiatives with institutions like Dartmouth College. The collection emphasizes factual reporting on phase transitions, financial disclosures, and operational updates without speculative commentary.
Content spans clinical trial authorizations, intellectual property developments, and executive leadership changes. Regular updates ensure stakeholders maintain current awareness of CYAD's progress in translating cell-based therapies from laboratory research to clinical applications.
Bookmark this page for streamlined access to verified CYAD developments. Combine periodic reviews with real-time monitoring for comprehensive analysis of the company's evolving role in advanced cancer treatment solutions.
Celyad Oncology (Euronext: CYAD) has announced the divestment of its research facility in Mont-Saint-Guibert, Belgium. The company will sell the facility's equipment and office furniture for €3 million.
The transaction, subject to customary conditions, is expected to close in Q4 2025. This strategic move is anticipated to extend the company's cash runway by approximately three quarters, reaching into Q3 2026.
Celyad Oncology (Euronext: CYAD) reported its financial results for H1 2025, showing a deteriorating financial position. The company's cash position dropped to €0.8 million as of June 30, 2025, compared to €4.2 million at the end of 2024. The net loss increased to €3.7 million (€0.09 per share) from €3.0 million (€0.07 per share) in H1 2024.
R&D expenses increased by €0.6 million to €2.1 million, primarily due to higher IP costs and catheter development expenses. G&A expenses remained stable at €1.7 million. The company projects its current cash position will only fund operations into Q4 2025, indicating potential liquidity concerns.
Celyad Oncology (CYAD) announced a significant change in its voting rights structure as CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, has passively crossed below the 60% threshold. The company now holds 34,146,795 voting rights, representing 59.41% of Celyad Oncology's total voting rights.
The change resulted from the maturation of double voting rights on shares issued during the September 2023 private placement. CFIP CLYD (UK) Limited's 7,954,808 shares now carry double voting rights, but due to another shareholder's larger stake also receiving double voting rights, their overall percentage decreased.
Celyad Oncology (Euronext: CYAD) has announced an update to its voting rights structure. As of September 4, 2025, the company reports that 3,849,040 registered shares now benefit from double voting rights. The company's share capital stands at €9,216,154.53, with a total of 44,761,905 shares outstanding, comprising 32,044,490 shares with single voting rights and 12,717,415 shares with double voting rights.
The total number of voting rights has reached 57,479,320. Additionally, there are 3,856,134 warrants outstanding, which could potentially create an equal number of shares with voting rights. On a fully diluted basis, the total number of shares would be 48,618,039 with 61,335,454 voting rights.
[]Celyad Oncology (Euronext: CYAD) has announced the discontinuation of its research and development activities and a significant reduction in its R&D workforce due to limited cash resources. The company will shift its focus to managing and licensing its intellectual property portfolio in CAR-T cell therapy.
CEO Matt Kane emphasized the company's commitment to supporting employees through the transition while exploring potential collaborations to leverage their IP assets. With cash resources expected to fund operations only until mid Q4 2025, Celyad is assessing strategic options and plans to sell remaining assets while maintaining strict cost-containment measures.
Celyad Oncology (Euronext: CYAD) has received a significant transparency notification from Fortress Investment Group LLC dated August 11, 2025. The notification reveals that CFIP CLYD (UK) Limited, a Fortress affiliate, has increased its voting rights to 32,691,987 shares, representing 60.96% of Celyad Oncology's total voting rights.
The threshold crossing occurred on August 5, 2025, following a capital increase where CFIP CLYD (UK) Limited received 3,333,333 additional shares. The transaction increased their holdings from their previous position of 29,358,654 voting rights, surpassing the statutory threshold of 60%.
Celyad Oncology (Euronext: CYAD) has announced changes to its share capital and voting rights structure following the issuance of 3,333,333 new shares to a Fortress Investment Group affiliate on August 5, 2025. The company's share capital has increased to €9,216,154.53, now represented by 44,761,905 total shares.
The updated structure includes 35,893,530 shares with single voting rights and 8,868,375 shares with double voting rights, totaling 53,630,280 voting rights. Additionally, there are 3,856,134 attributed warrants that could potentially create an equal number of shares with voting rights.
Celyad Oncology (Euronext: CYAD) has secured a €1 million private placement through a subscription agreement with CFIP CLYD (UK) Limited (Fortress). The deal involves issuing 3,333,333 new ordinary shares at €0.30 per share, representing a 15% discount to the 10-day VWAP on Euronext Brussels.
Following the transaction, expected to close around August 5, 2025, Fortress will hold approximately 58.51% of the company's shares. The proceeds will support working capital and general corporate purposes, extending Celyad's cash runway from mid-Q3 2025 to mid-Q4 2025, providing additional time to evaluate strategic options for strengthening its balance sheet.
Celyad Oncology (NASDAQ:CYAD) has announced a comprehensive strategic review amid financial challenges. The company reported a treasury position of €4.2 million as of December 31, 2024, with cash runway only extending into Q3 2025. The review encompasses potential asset sales, restructuring, mergers, and financing options.
The company has already implemented cost-reduction measures, with R&D expenses decreasing to €3.2 million in 2024 (from €4.6 million in 2023) and G&A expenses reducing to €3.2 million (from €6.0 million in 2023). Celyad is currently in discussions for potential out-licensing deals on its CAR-T and shRNA platforms.
Celyad Oncology has reported its full year 2024 financial results, showing a net loss of €5.8 million (€0.14 per share), improved from €8.5 million loss in 2023. The company's treasury position stands at €4.2 million as of December 31, 2024.
Key operational highlights include advancement of their multiplex miRNA-based shRNA non-gene editing technology to a 5-plex system and development of multispecific NKG2D-based CAR T-cell platform. The company has also re-initiated manufacturing of C-Cath®, an intra-myocardial injection catheter.
Financial metrics show reduced R&D expenses at €3.2 million (down from €4.6 million in 2023) and G&A expenses at €3.2 million (down from €6.0 million). Net cash used in operations decreased significantly to €2.8 million from €15.2 million in 2023. The company projects its current cash position will fund operations into Q3 2025.
FAQ
What is the market cap of CYAD (CYAD)?
